The FDA will discuss a New Drug Application for Remoxy ER during an upcoming advisory committee meeting and recently approved tildrakizumab-asmn to treat adults with plaque psoriasis…
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
(Reuters)—AbbVie Inc. on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc. that would fend off U.S. competition of their biosimilar version to blockbuster drug, adalimumab (Humira), until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira,…
The ACR Updates Biosimilar Position Statement
In March, the ACR released a white paper designed primarily to help rheumatologists and rheumatology health professionals gain an understanding of biosimilars.1 This research-based education piece examines the scientific, economic and prescribing issues related to the use of biosimilars. Now, the ACR has released an update to its official position statement on the use of…
Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs
A recent study examined how often patients exceed the dosing limits of nonsteroidal anti-inflammatory drugs and identified the characteristics of the patients most likely to exceed recommended doses…
Many in U.S. Take More Calcium Supplements than Necessary
(Reuters Health)—Some adults in the U.S. who use supplements to get their daily requirement of calcium are taking higher doses than necessary, a recent study suggests. Researchers examined nationally representative survey data on dietary habits and vitamin and supplement use collected between 1999 and 2014 from 42,038 adults. About one in 20 adults got a…
Abaloparatide Appears Safe, Effective for Boosting BMD in Women 80 & Up
NEW YORK (Reuters Health)—Abaloparatide appears to be a safe and effective drug for increasing bone mineral density (BMD) in women 80 and older, new research shows. The study is a post hoc analysis of the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, which found patients who received abaloparatide subcutaneously for 18 months had increased…
Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
NEW YORK (Reuters Health)—After discontinuation of teriparatide, increases in bone mineral density (BMD) are greater with denosumab than with zoledronic acid, but whether that translates into a decreased fragility fracture risk remains unknown, researchers say. Teriparatide was the first anabolic treatment approved for osteoporosis in the U.S. It has been shown to increase BMD, and…
FDA’s Gottlieb Eyes PBM Consolidation Impact on Generic Entry: CNBC
NEW YORK (Reuters)—The head of the U.S. Food & Drug Administration Scott Gottlieb said on Wednesday that he was concerned about the impact of deals like the CVS Health purchase of Aetna Inc. on the ability of pharmaceutical companies to block the entry of cheaper copycat drugs. As the pharmacy benefit managers and the drug…
Dermatology Patients on Corticosteroids May Not Receive Osteoporosis Screenings; Plus FDA Approves ZTLido
A recent study found that dermatology patients taking long-term steroids are not always evaluated for steroid-induced osteoporosis…
Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients
As medical and recreational marijuana becomes more accessible, researchers seek creative ways to study the cannabis plant and explore the complexities of the endocannabinoid system in pain relief. Rheumatologists currently face an influx of patients asking if marijuana can help them. Here’s a look at the evolving research on cannabinoids for rheumatologic pain management and how doctors are discussing it with their patients…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 121
- Next Page »